Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Jayakanth Kankanala; Karen A. Kirby; Andrew D. Huber; Mary C. Casey; Daniel J. Wilson; Stefan G. Sarafianos; Zhengqiang Wang

doi:10.1016/j.ejmech.2017.09.054

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Jayakanth Kankanala, Karen A. Kirby, Andrew D. Huber, Mary C. Casey, Daniel J. Wilson, Stefan G. Sarafianos, Zhengqiang Wang

Center for Drug Design

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC₅₀ = 0.04 μM) with decent antiviral potency (EC₅₀ = 7.4 μM) and no cytotoxicity (CC₅₀ > 100 μM). In extended biochemical assays compound 11d did not inhibit RT polymerase (pol) while inhibiting integrase strand transfer (INST) with 53 fold lower potency (IC₅₀ = 2.1 μM) than RNase H inhibition. Crystallographic and molecular modeling studies confirmed the RNase H active site binding mode.

Original language	English (US)
Pages (from-to)	149-161
Number of pages	13
Journal	European Journal of Medicinal Chemistry
Volume	141
DOIs	https://doi.org/10.1016/j.ejmech.2017.09.054
State	Published - Dec 1 2017

Bibliographical note

Funding Information:
This research was supported in part by the National Institutes of Health ( AI100890 to SGS and ZW), and by the Research Development and Seed Grant Program of the Center for Drug Design, University of Minnesota . Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy ( DOE ) Office of Science by Argonne National Laboratory , was supported by the U.S. DOE under Contract No. DE-AC02-06CH11357 . We also thank Drs. Michail Isupov and Ronan Keegan of BioMEX Solutions, Inc. for assistance with structure solution and refinement. Appendix A

Publisher Copyright:
© 2017 Elsevier Masson SAS

Keywords

Human immunodeficiency virus (HIV)
Integrase strand transfer
Molecular modeling and crystallography
N-Hydroxy thienopyrimidine-2,4-diones
RNase H
RT-Polymerase

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.ejmech.2017.09.054

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682218

OpenUrl availability

Full text

Cite this

@article{996d8a022511462290c934054e06d070,

title = "Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H",

abstract = "Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC50 = 0.04 μM) with decent antiviral potency (EC50 = 7.4 μM) and no cytotoxicity (CC50 > 100 μM). In extended biochemical assays compound 11d did not inhibit RT polymerase (pol) while inhibiting integrase strand transfer (INST) with 53 fold lower potency (IC50 = 2.1 μM) than RNase H inhibition. Crystallographic and molecular modeling studies confirmed the RNase H active site binding mode.",

keywords = "Human immunodeficiency virus (HIV), Integrase strand transfer, Molecular modeling and crystallography, N-Hydroxy thienopyrimidine-2,4-diones, RNase H, RT-Polymerase",

author = "Jayakanth Kankanala and Kirby, {Karen A.} and Huber, {Andrew D.} and Casey, {Mary C.} and Wilson, {Daniel J.} and Sarafianos, {Stefan G.} and Zhengqiang Wang",

note = "Funding Information: This research was supported in part by the National Institutes of Health ( AI100890 to SGS and ZW), and by the Research Development and Seed Grant Program of the Center for Drug Design, University of Minnesota . Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy ( DOE ) Office of Science by Argonne National Laboratory , was supported by the U.S. DOE under Contract No. DE-AC02-06CH11357 . We also thank Drs. Michail Isupov and Ronan Keegan of BioMEX Solutions, Inc. for assistance with structure solution and refinement. Appendix A Publisher Copyright: {\textcopyright} 2017 Elsevier Masson SAS",

year = "2017",

month = dec,

day = "1",

doi = "10.1016/j.ejmech.2017.09.054",

language = "English (US)",

volume = "141",

pages = "149--161",

journal = "European Journal of Medicinal Chemistry",

issn = "0223-5234",

publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

AU - Kankanala, Jayakanth

AU - Kirby, Karen A.

AU - Huber, Andrew D.

AU - Casey, Mary C.

AU - Wilson, Daniel J.

AU - Sarafianos, Stefan G.

AU - Wang, Zhengqiang

N1 - Funding Information: This research was supported in part by the National Institutes of Health ( AI100890 to SGS and ZW), and by the Research Development and Seed Grant Program of the Center for Drug Design, University of Minnesota . Use of the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy ( DOE ) Office of Science by Argonne National Laboratory , was supported by the U.S. DOE under Contract No. DE-AC02-06CH11357 . We also thank Drs. Michail Isupov and Ronan Keegan of BioMEX Solutions, Inc. for assistance with structure solution and refinement. Appendix A Publisher Copyright: © 2017 Elsevier Masson SAS

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC50 = 0.04 μM) with decent antiviral potency (EC50 = 7.4 μM) and no cytotoxicity (CC50 > 100 μM). In extended biochemical assays compound 11d did not inhibit RT polymerase (pol) while inhibiting integrase strand transfer (INST) with 53 fold lower potency (IC50 = 2.1 μM) than RNase H inhibition. Crystallographic and molecular modeling studies confirmed the RNase H active site binding mode.

AB - Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have shown significant antiviral activities. We report herein the design, synthesis and biological evaluation of a novel N-hydroxy thienopyrimidine-2,3-dione chemotype (11) which potently and selectively inhibited RNase H with considerable potency against HIV-1 in cell culture. Current structure-activity-relationship (SAR) identified analogue 11d as a nanomolar inhibitor of RNase H (IC50 = 0.04 μM) with decent antiviral potency (EC50 = 7.4 μM) and no cytotoxicity (CC50 > 100 μM). In extended biochemical assays compound 11d did not inhibit RT polymerase (pol) while inhibiting integrase strand transfer (INST) with 53 fold lower potency (IC50 = 2.1 μM) than RNase H inhibition. Crystallographic and molecular modeling studies confirmed the RNase H active site binding mode.

KW - Human immunodeficiency virus (HIV)

KW - Integrase strand transfer

KW - Molecular modeling and crystallography

KW - N-Hydroxy thienopyrimidine-2,4-diones

KW - RNase H

KW - RT-Polymerase

UR - http://www.scopus.com/inward/record.url?scp=85030841963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030841963&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2017.09.054

DO - 10.1016/j.ejmech.2017.09.054

M3 - Article

C2 - 29031062

AN - SCOPUS:85030841963

SN - 0223-5234

VL - 141

SP - 149

EP - 161

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

ER -

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this